Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun;18(6):RA97-103.
doi: 10.12659/msm.882868.

Ophthalmic transplantology: posterior segment of the eye--part II

Małgorzata Nita  1 , Barbara Strzałka-Mrozik, Andrzej Grzybowski, Wanda Romaniuk, Urszula Mazurek
Affiliations
Review

Ophthalmic transplantology: posterior segment of the eye--part II

Małgorzata Nita et al. Med Sci Monit. 2012 Jun.

Abstract

Background: Transplants of the retina are among the new strategies being used in the treatment of genetic and degenerative macular diseases. Moreover, various cell cultures are being tested to treat retinal disorders.

Material/methods: Literature dated from 2004 to 2011 was comprehensively examined via Medline and PubMed searches for the following terms: auto-, homo-, heterologous transplantation, retina, stem cells, cultivated cells.

Results: Tissue and cell therapy of retinal diseases are reviewed, including full-thickness retina/retinal pigment epithelium (RPE)/choroid graft; full and partial thickness RPE/choroid complex grafts; RPE/Bruch membrane complex graft; and RPE, iris pigment epithelium and stem cell grafts. Recommendations for transplants, as well as the benefits and weaknesses of specific techniques in retina transplants, are discussed.

Conclusions: Auto- and allogenic transplants of a full or partial thickness retina/RPE/ Bruch membrane/choroid complex represent an alternative treatment offered to patients with some macular diseases. Stem cell transplantation to reconstruct and regenerate the macula requires further biomolecular and animal research studies.

PubMed Disclaimer

References

    1. Detrick B, Hooks JJ. Immune regulation in the retina. Immunol Res. 2010;47:153–61. - PMC - PubMed
    1. Nussenblatt RB, Liu B, Li Z. Age-related macular degeneration: an immunologically driven disease. Curr Opin Investig Drugs. 2009;10:434–42. - PubMed
    1. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009;28:1–18. - PMC - PubMed
    1. Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic therapy with verteporfin in age-related macular degeneration: asystematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol. 2009;87(2):118–32. - PubMed
    1. Schmidt-Erfurth U, Kiss C, Sacu S. The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies. Prog Retin Eye Res. 2009;28(2):145–54. - PubMed

Publication types